248 related articles for article (PubMed ID: 10760774)
1. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
2. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
3. Bilateral adrenal neuroblastoma.
Zaizen Y; Suita S; Yamanaka K; Nagoshi M; Tsuda T
Eur J Pediatr Surg; 1997 Oct; 7(5):304-7. PubMed ID: 9402493
[TBL] [Abstract][Full Text] [Related]
4. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
5. Bilateral adrenal neuroblastoma is different.
Pederiva F; Andres A; Sastre A; Alves J; Martinez L; Tovar JA
Eur J Pediatr Surg; 2007 Dec; 17(6):393-6. PubMed ID: 18072022
[TBL] [Abstract][Full Text] [Related]
6. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
7. Composite pheochromocytoma: a clinicopathologic and molecular comparison with ordinary pheochromocytoma and neuroblastoma.
Comstock JM; Willmore-Payne C; Holden JA; Coffin CM
Am J Clin Pathol; 2009 Jul; 132(1):69-73. PubMed ID: 19864235
[TBL] [Abstract][Full Text] [Related]
8. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
9. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
[TBL] [Abstract][Full Text] [Related]
10. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397
[TBL] [Abstract][Full Text] [Related]
11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
12. A neuroblastoma cell line derived from a case detected through a mass screening system in Japan: a case report including the biologic and phenotypic characteristics of the cell line.
Hiraiwa H; Hamazaki M; Takata A; Kikuchi H; Hata J
Cancer; 1997 May; 79(10):2036-44. PubMed ID: 9149033
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening.
Matsunaga T; Shirasawa H; Hishiki T; Yoshida H; Kouchi K; Ohtsuka Y; Kawamura K; Etoh T; Ohnuma N
Clin Cancer Res; 2000 Aug; 6(8):3199-204. PubMed ID: 10955804
[TBL] [Abstract][Full Text] [Related]
14. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
15. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
Matsunaga T; Takahashi H; Ohnuma N; Tanabe M; Yoshida H; Iwai J; Shirasawa H; Simizu B
Cancer Res; 1991 Jun; 51(12):3148-52. PubMed ID: 2039993
[TBL] [Abstract][Full Text] [Related]
16. Biological aspects of neuroblastomas identified by mass screening in Quebec.
Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
[TBL] [Abstract][Full Text] [Related]
17. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
18. The characteristics of mediastinal neuroblastoma.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Tasaka H; Yano H; Akiyama H; Ikeda K
Eur J Pediatr Surg; 2000 Dec; 10(6):353-9. PubMed ID: 11215774
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
[TBL] [Abstract][Full Text] [Related]
20. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]